Answer
Selexipag’s active metabolite is approximately 37-fold more potent at the IP receptor than selexipag.
Sources for this answer
- Uptravi 200 microgram film-coated tablets (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §5.1 Pharmacodynamic properties · Version 19Document updated
Sources checked